CRVS Stock Overview
A clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Corvus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.48 |
| 52 Week High | US$4.75 |
| 52 Week Low | US$1.05 |
| Beta | 1.13 |
| 11 Month Change | 50.34% |
| 3 Month Change | 101.80% |
| 1 Year Change | 109.35% |
| 33 Year Change | 63.50% |
| 5 Year Change | 6.92% |
| Change since IPO | -68.56% |
Recent News & Updates
Recent updates
Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy
Sep 02Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?
Mar 06
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Oct 23Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?
May 16Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Dec 05Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China
Sep 26We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate
Aug 14Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
Apr 05We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely
Dec 15Checking In On Corvus Pharmaceuticals
Dec 10Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming
Sep 22We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Aug 26Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target
May 27Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?
May 08The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares
Feb 19Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Feb 07Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like
Dec 16Corvus Pharmaceuticals EPS misses by $0.06
Oct 29Shareholder Returns
| CRVS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.1% | -0.2% | 0.5% |
| 1Y | 109.3% | 14.0% | 22.7% |
Return vs Industry: CRVS exceeded the US Biotechs industry which returned 14% over the past year.
Return vs Market: CRVS exceeded the US Market which returned 22.7% over the past year.
Price Volatility
| CRVS volatility | |
|---|---|
| CRVS Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRVS's share price has been volatile over the past 3 months.
Volatility Over Time: CRVS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 28 | Rick Miller | www.corvuspharma.com |
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer.
Corvus Pharmaceuticals, Inc. Fundamentals Summary
| CRVS fundamental statistics | |
|---|---|
| Market cap | US$280.23m |
| Earnings (TTM) | -US$22.62m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-12.4x
P/E RatioIs CRVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRVS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$22.62m |
| Earnings | -US$22.62m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CRVS perform over the long term?
See historical performance and comparison